Pembrolizumab + Gemcitabine + Vinorelbine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesothelioma Malignant Advanced
Conditions
Pleural Mesothelioma Malignant Advanced
Trial Timeline
Sep 12, 2017 → Nov 30, 2021
NCT ID
NCT02991482About Pembrolizumab + Gemcitabine + Vinorelbine
Pembrolizumab + Gemcitabine + Vinorelbine is a phase 3 stage product being developed by Merck for Pleural Mesothelioma Malignant Advanced. The current trial status is completed. This product is registered under clinical trial identifier NCT02991482. Target conditions include Pleural Mesothelioma Malignant Advanced.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02991482 | Phase 3 | Completed |
Competing Products
20 competing products in Pleural Mesothelioma Malignant Advanced